Mabwell presents Phase II trial results for breast cancer drug 9MW2821
Biopharmaceutical firm Mabwell scheduled Phase II clinical trial data presentations for its Nectin 4 targeting antibody drug conjugate 9MW2821 at the European Society for Medical Oncology Congress
SHANGHAI, Oct. 19, 2026 - Mabwell, a biopharmaceutical company based in Shanghai, will showcase Phase II clinical data on its Nectin-4-targeting antibody-drug conjugate (ADC) 9MW2821 during the 2026 European Society for Medical Oncology (ESMO) Congress. The study examines the potential of 9MW2821 in patients with locally advanced or metastatic triple-negative breast cancer (TNBC) who have previously received an ADC containing topoisomerase I inhibitor payload.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
